Cellectar Biosciences Faces Pivotal Week with Dual Catalysts

Investors in Cellectar Biosciences are bracing for significant volatility as the company approaches two major developments that could dramatically influence its stock trajectory. The biopharmaceutical firm stands at a critical juncture with both regulatory and clinical milestones converging within days.

According to recent quarterly reports, Cellectar maintains sufficient liquidity to fund operations through the second quarter of 2026, providing a stable financial backdrop during this period of potential transformation. The most immediate catalyst involves the European Medicines Agency (EMA), which is expected to issue its decision on conditional marketing authorization for iopofosine I 131 within days. This investigational compound targets Waldenstrom Macroglobulinemia and has previously earned multiple regulatory designations, including the EMA’s PRIME status, recognizing its potential therapeutic value.

Expanding... Read more...